Patheon signs technology transfer deal with Dendreon
Promising new therapy for hormone refractory protate cancer
Drug development and manufacturing services Patheon has signed a technology transfer agreement with Dendreon Corporation for commercial supply of proprietary density gradient solutions required during the PROVENGE (sipuleucel-T) manufacturing process.
PROVENGE was approved by the US FDA at the end of April 2010 for the treatment of asymptomatic or minimally symptomatic castrate resistant (hormone refractory) prostate cancer. It is the first autologous cellular immunotherapy to be approved by the FDA and is based on a unique technology platform.
‘We are very excited that Dendreon has chosen Patheon to help bring to market this promising new therapy,’ said Wes Wheeler, Patheon's ceo and president. ‘We have dedicated ourselves to understanding our customer's needs and developing both the capability and capacity to deliver on those needs. We're happy that Dendreon has trusted us to be part of the commercialisation of this product.’
